GSK Advances mRNA Influenza Vaccine Towards Late-Stage Trials
The British pharmaceutical giant GSK made a significant stride in the fight against seasonal influenza by announcing positive results from a mid-stage trial of its mRNA-based flu vaccine. This promising development signals a critical step towards late-stage clinical trials, as GSK aims to enhance its vaccine portfolio and address current limitations in flu protection. The…









